✓
Open
23 Sep 2025
✓
Close
25 Sep 2025
3
Allotment
—
✓
Listing
Tue, Sep 30, 2025
Price Band
₹65 to ₹70
Issue Size
18,60,000 shares (agg. up to ₹13 Cr)
Lot Size
2,000 Shares
Listing Date
Tue, Sep 30, 2025
Latest GMP
₹4
Est. Gain
5.71%
✦ AI Insight
GMP Trend
30-09-2025₹4Est. ₹74+5.71%
29-09-2025₹4Est. ₹74+5.71%
28-09-2025₹4Est. ₹74+5.71%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 16.28x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 21.92 | 10.03 | 6.22 |
| Total Income | 24.64 | 17.88 | 13.90 |
| Profit After Tax | 3.10 | 0.80 | 0.19 |
| EBITDA | 4.76 | 1.49 | 0.57 |
| NET Worth | 6.97 | 1.77 | 0.97 |
| Reserves and Surplus | 1.97 | 1.47 | 0.67 |
| Total Borrowing | 10.36 | 5.31 | 2.21 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | 17.83 | ₹124.95 | +1.59% | ₹73.50 (-2.00%) |
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | 13.04 | ₹126.20 | +31.46% | ₹290.00 (-0.60%) |
| Astonea Labs Ltd. | SME | ₹37.67 Cr | ₹135 | 27.36 | ₹135.65 | +0.48% | ₹283.00 (-1.57%) |
| Accretion Pharmaceuticals Ltd. | SME | ₹29.75 Cr | ₹101 | 21.29 | ₹82.95 | -17.87% | ₹166.00 (+3.33%) |
| Amwill Health Care Ltd. | SME | ₹59.98 Cr | ₹111 | 13.81 | ₹93.25 | -15.99% | ₹42.11 (+2.71%) |
| Sat Kartar Shopping Ltd. | SME | ₹33.80 Cr | ₹81 | 14.87 | ₹161.55 | +99.44% | ₹130.00 (-1.59%) |
| Onyx Biotec Ltd. | SME | ₹29.34 Cr | ₹61 | 26.81 | ₹56.75 | -6.97% | ₹39.55 (+4.91%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹165.27 (-1.98%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.18 (+0.53%) |
| Senores Pharmaceuticals Ltd. | Mainboard | ₹582.11 Cr | ₹391 | 39.77 | ₹557.80 | +42.66% | ₹1,452.90 (-1.74%) |
| Sai Life Sciences Ltd. | Mainboard | ₹3,042.62 Cr | ₹549 | 126.42 | ₹764.65 | +39.28% | ₹1,294.90 (+2.45%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capital Expenditure for Office Premises with furniture and Industrial Racks | 1.63 |
| 2 | Working Capital | 8.00 |
| 3 | General Corporate Purposes | 1.91 |
| 4 | Issue Expenses | 1.48 |
| Total | 13.02 |
About Aptus Pharma IPO
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing, and distribution of finished pharmaceutical formulations The company manufactures and distributors of a broad range of pharmaceutical formulations covering multiple therapeutic areas: antacids & PPIs, pain management, anti-inflammatories, antibiotics, cardiology & antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, sachets, and more. Products: Aptus Pharma: Focuses on acute therapies i.e, anti-infectives, pain management, etc. Aptus CD care: Focused on chronic therapies Aptus Wellcare: Offers wellness and nutraceutical products Aptus Global: Export in overseas market As of March 31, 2025, the company has 194 pharmaceutical formulations in more than eleven therapeutic segments. Its warehouse is located over 15,732 sq. Feet and 1989 sq. feet in Ahmedabad, Gujarat. Its distribution model includes 125 direct and sub distributors and a sales team of 54 field personnel. As of March 31, 2025, the company had 70 employees. Competitive Strengths Diversified product portfolio Robust distribution network Strategic manufacturing alliances across Gujarat, Uttarakhand and Himachal
Contact Details
Aptus Pharma Ltd. AddressAshutosh Buildcon, Opp.Slok-2Nr.Harikrupa Logistic ParkAslali, DaskroiAhmedabad, Gujarat, 382427+91 76004 27827info@aptuspharma.comVisit Website